Welcome to our dedicated page for Applied Uv Series A Preferred Stock news (Ticker: AUVIP), a resource for investors and traders seeking the latest updates and insights on Applied Uv Series A Preferred Stock stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied Uv Series A Preferred Stock's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied Uv Series A Preferred Stock's position in the market.
Applied UV (NASDAQ:AUVI) has authorized a cash dividend of $0.21875 per share for holders of its 10.5% Series A Cumulative Perpetual Preferred Stock (NASDAQ:AUVIP). The dividend payment is scheduled for on or about March 15, 2022, to shareholders of record as of March 4, 2022. The company focuses on pathogen elimination technologies through UVC light, targeting healthcare and other sectors.
Applied UV (NASDAQ:AUVI, AUVIP) announced that underwriters exercised an over-allotment option to purchase an additional 400,000 shares of common stock, generating approximately $1.2 million in gross proceeds. This was part of a previously completed public offering of 2,666,667 shares priced at $3.00 per share. The offering's registration statement was declared effective on December 28, 2021, with a final prospectus filed shortly after. The funds raised will support Applied UV's focus on infection control technology in various markets.
Applied UV (NASDAQ: AUVI, AUVIP) has closed its underwritten public offering of 2,666,667 shares at $3.00 per share, generating approximately $8.0 million in gross proceeds. The company has also granted the underwriters a 45-day option to purchase up to an additional 400,000 shares to cover over-allotments. The proceeds will be used for general corporate purposes, including investments and acquisitions. The offering's registration was effective on December 28, 2021, and the final prospectus was filed on December 30, 2021.
Applied UV (NASDAQ:AUVI, AUVIP) has announced an underwritten public offering of 2,666,667 shares of common stock, priced at $3.00 per share, aiming to raise approximately $8.0 million before expenses. The offering is set to close around December 31, 2021, pending customary conditions. The net proceeds will support general corporate needs, including investments and acquisitions. Additionally, underwriters have a 45-day option to purchase an extra 400,000 shares for over-allotments. EF Hutton is the book-running manager for this offering.
Applied UV (NASDAQ: AUVI) has authorized a cash dividend of $0.21875 per share for holders of its 10.5% Series A Cumulative Perpetual Preferred Stock (NASDAQ: AUVIP). This dividend will be paid on or about August 16, 2021, to shareholders on record as of August 4, 2021. The company focuses on infection control technology, utilizing UVC light for disinfecting surfaces and air purification through its proprietary technologies, including Airocide and Lumicide.